Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Summary

RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by the body. It is not yet known whether radiation therapy is more effective with or without androgen-deprivation therapy in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.

Timeline

Start

2009-09

Primary completion

2020-10-03

Completion

2025-09-04

Outcome

Missed primary endpoint

paper Five-year OS estimates were 90% versus 91%, respectively (hazard ratio [HR], 0.85; 95% CI, 0.65 to 1.11]; P = .22). PMID 37104748 ↗

paper CONCLUSION: STAD did not improve OS rates for men with IRPC treated with dose-escalated RT. PMID 37104748 ↗

Publications

• Krauss DJ, Karrison T, Martinez AA, Morton G, Yan D, Bruner DW, Movsas B, Elshaikh M, Citrin D, Hershatter B, Michalski JM, Efstathiou JA, Currey A, Kavadi VS, Cury FL, Lock M, Raben A, Seaward SA, El-Gayed A, Rodgers JP, Sandler HM. Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial. J Clin Oncol. 2023 Jun 10;41(17):3203-3216. doi: 10.1200/JCO.22.02390. Epub 2023 Apr 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bicalutamide	Other / unclassified	50 mg	Oral
Subject	Degarelix	Other / unclassified	—	—
Subject	Flutamide	Small molecule	250 mg	Oral
Subject	Goserelin	Other / unclassified	—	—
Subject	Leuprolide	Other / unclassified	—	—
Subject	Triptorelin	Other / unclassified	—	—
Subject	buserelin	Unknown	—	—

Indications